drugset / Trial / NCT07115654
BCMA/CD3 BsAb Therapy for POEMS Syndrome
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, investigator-initiated clinical trial evaluating the safety and efficacy of a BCMA/CD3 bispecific antibody (CM336) in patients with POEMS syndrome.
Timeline
- Start
- 2025-08-04
- Primary completion
- 2026-12-01
- Completion
- 2027-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CM336 | Monoclonal antibody | — | — |